Back to search

Article

Cefto-Reallife Study: Real World Data on the Use of Ceftobiprole in a Multicenter Spanish Cohort

2023-06-21

Abstract excerpt

<h4>Background: </h4> Ceftobiprole is a fifth-generation cephalosporin that has been approved in Europe solely for the treatment of community-acquired and nosocomial pneumonia. The objective was to analyze the use of ceftobiprole medocaril (Cefto-M) in Spanish clinical practice in patients with infection in hospital or outpatient parenteral antimicrobial therapy (OPAT). <h4>Methods:</h4> This retrospective, observ...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
04b57733-cc8a-5308-9b82-e347ac6ea819
DOI
10.20944/preprints202306.1477.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cefto-Reallife Study: Real World Data on the Use of Ceftobiprole in a Multicenter Spanish CohortDOI 10.20944/preprints202306.1477.v1
Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE StudySemantic proximity
Real‑world effectiveness and safety of cefiderocol in critically ill patients with MDR Gram‑negative infections: Results from a retrospective studySemantic proximity
Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-IDSemantic proximity
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR- P. aeruginosa )Semantic proximity
Antimicrobial activity of ceftobiprole and comparator agents when tested against Gram-positive and -negative organisms collected across China (2016-2018)Semantic proximity
Beyond the Prescription Pad: “Unveiling Outpatient Antimicrobial Patterns”Semantic proximity
Introducing the new face of CLSI M100 in 2023: An explanatory reviewSemantic proximity
In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates.Semantic proximity
Antimicrobial resistance and beta-lactamase gene distribution among clinical isolates: a two-year cohort studySemantic proximity
Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in ChildrenSemantic proximity
P095: The 2nd/3rd generation of cephalosprines use in antimicrobial stewardship program and contemporary carriage of E. coli and K. pneumoniae with esbls from identified or suspected infection hospitalized patientsSemantic proximity
Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program.Semantic proximity
Select a neighboring publication to make it the new centre.